- Email: [email protected]
PDT Brazil - Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences
Abstracts / Photodiagnosis and Photodynamic Therapy 12 (2015) 325–375
373
PDT Brazil - Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences
effective therapeutic approach in the treatment of superficial BCC, with maintenance
Romero Paulina 1,2 , Cabrera Franklin 1,2 , Tello Sonia 1,2 , Kurachi Cristina 1,2 , Ramirez Patricia 1,2 , Guamán Leonel 1,2 , Avalos Eduardo 1,2 , Bagnato Vanderlei 1,2
http://dx.doi.org/10.1016/j.pdpdt.2015.07.187
1 Escuela Politécnica Nacional, Departamento de Materiales, Eléctrica y Física Quito-Ecuador. Hospital Carlos Andrade Marín, Servicio de Dermatología e Histopatología. Quito – Ecuador 2 São Carlos Institute of Physics, University of Sao Paulo, Brazil
In Ecuador the National Tumor Registry (RNT) show in 2002 the non-melanoma skin cancer was the second most common cancer in men and women, but in 2005 it takes the first place for women. Experience: 11 patients with surface CBC, 47 with nodular CBC, 2 with CBC recurrences (depht middle dermis), 2 with CBC recurrences (neural invasion) and 3 with surface CEC, were treated with Photodynamic therapy based in Metil -ALA 20% and the LINCE light source with 100 W/cm2 , 635nm wavelength. During treatment was used the dermatoscopy to monitor lesions. The results were evaluated by histopathological studies where the initial depth of the lesions was evident. These assessments allowed to find the depth at which treatment is efficient. Patients were treated between 2012 - 2014 in the “Carlos Andrade Marín” Hospital and “Gonzalo Gonzalez” Dermatological Hospital in Quito- Ecuador. Results: After 2 therapy sessions for suface CBC (depht middle dermis) 90% of the patients have a complete response, for nodular CBC after 4 sessions 86% of the patients have a complete response, for the CBC recurrences (neural invasion) don’t show an effective response, and for surface CEC after 6 sessions 100% of the patients have a complete response. http://dx.doi.org/10.1016/j.pdpdt.2015.07.186
PDT Brazil - Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months L.I.S. Mota, M.F.M. Brito, J.S. Belo Universidade Federal de Pernambuco - Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months. Fundamentals: Basal-cell cancer is the most prevalent non-melanoma skin cancer in Brazil and worldwide. Photodynamic therapy (PDT) is a noninvasive technique with excellent cosmetic outcome and curative results. Maintaining cure rates remains an object of study due to the recent introduction of this therapy in dermatology. Objective: Evaluate the clinical response of photodynamic therapy in superficial basal-cell carcinoma after 12 months of treatment in patients with initial complete response at the end of the third month after treatment. Methods: After curettage and application of methyl aminolevulinate, the lesion was occluded for 3 hours. Then it was discovered and submitted a 635nm LED (37 J/cm2 ), positioned eight centimeters from the patient, for eight minutes. Two sessions were realized with intervals of 14 days. Pictures were performed before treatment, at 3 and 12 months after treatment. Results: The analyses involved 35 patients, that were submitted a MAL-PDT and presented complete response in the evaluation of three months. These cancers were checked with 12 months. A maintenance of complete clinical response was observed in 85% (30/35). Conclusion: PDT-MAL is a safe and
PDT Brazil - A New Approach for Basal Cell Carcinoma Treatment Kate C. Blanco, Natalia M. Inada, Ana Paula da Silva, Pedro Russignoli, Dora P. Ramirez, Hilde H. Buzzá, Mirian D. Stringasci, Lilian T. Moriyama, Clovis Grecco, Cristina Kurachi, Vanderlei S. Bagnato São Carlos Institute of Physics, University of Sao Paulo, Brazil Non-melanoma skin cancer (NMSC) is the most prevalent cancer type in Brazil and worldwide. According to the National Institute of Cancer (INCA) at the last year, it was estimated 182,130 new cases of NMSC in Brazil. Photodynamic Therapy (PDT) has proven to be effective with an excellent cosmetic outcome and reliable treatment option. A Brazilian program was established to determine the efficacy of topical MAL-PDT using a Brazilian device (LINCE, MMOptics, Brazil) and medication (methyl aminolevulinate, PDTPharma, Brazil). During four years with financial support by BNDES (Brazilian Development Bank), we are reporting the treatment of 994 basal cell carcinoma (BCC), around all country and Latin America. Through these data it was analyzed the efficiency of the treatment 30 days after the second PDT session. Were compared the gender, age, skin type, location and size of the lesions. The conclusion of this extensive and important project has shown the efficacy PDT with 81.7% of clearance of superficial BCC and 75.1% for nodular BCC, and a small relapse rate of 1.22%. http://dx.doi.org/10.1016/j.pdpdt.2015.07.188 Prospective, double-blind, randomized placebo-controlled trial of the efficacy of lidocaine and tetracaine cream 7%/7% for pain control during PDT Ana Gabriela Salvio 1 , Pedro E Russignoli 2 , Natalia Mayumi Inada 2 , Elisangela Ramos de Oliveira 1 , Cristina Kurachi 2 , Vanderlei Salvador Bagnato 2 1 Skin Deppartment of Amaral Carvalho Hospital, Brazil 2 São Carlos Institute of Physics, University of Sao Paulo, Brazil
Photodynamic therapy (PDT) for basal cell carcinoma (BCC) treatment has been shown to be an excellent alternative to surgery, providing complete response rate of around 90% with good aesthetical outcome. However, a large proportion of patients complain local pain during irradiation, with an intensity that varies from mild to severe, and in some cases required momentary management, such as interruption of the session, nerve blocks or tumescent anaesthesia. In order to find an effective and minimally invasive strategy for the pain control during PDT, it was proposed a randomized, double-blind placebo-controlled study. Forty nodular BCC lesions less than 2 mm infiltration was selected and divided in four groups: (1) application of a FDA-approved topical anesthetic cream (Pliaglis®, Galderma, lidocaine and tetracaine cream 7%/7%) 30 minutes before illumination; (2) placebo cream application 30 minutes before illumination; (3) application of anesthetic cream immediately before illumination; (4) application of placebo cream
373
PDT Brazil - Photodynamic Therapy based M-ALA for non melanoma skin cancer: Ecuador experiences
effective therapeutic approach in the treatment of superficial BCC, with maintenance
Romero Paulina 1,2 , Cabrera Franklin 1,2 , Tello Sonia 1,2 , Kurachi Cristina 1,2 , Ramirez Patricia 1,2 , Guamán Leonel 1,2 , Avalos Eduardo 1,2 , Bagnato Vanderlei 1,2
http://dx.doi.org/10.1016/j.pdpdt.2015.07.187
1 Escuela Politécnica Nacional, Departamento de Materiales, Eléctrica y Física Quito-Ecuador. Hospital Carlos Andrade Marín, Servicio de Dermatología e Histopatología. Quito – Ecuador 2 São Carlos Institute of Physics, University of Sao Paulo, Brazil
In Ecuador the National Tumor Registry (RNT) show in 2002 the non-melanoma skin cancer was the second most common cancer in men and women, but in 2005 it takes the first place for women. Experience: 11 patients with surface CBC, 47 with nodular CBC, 2 with CBC recurrences (depht middle dermis), 2 with CBC recurrences (neural invasion) and 3 with surface CEC, were treated with Photodynamic therapy based in Metil -ALA 20% and the LINCE light source with 100 W/cm2 , 635nm wavelength. During treatment was used the dermatoscopy to monitor lesions. The results were evaluated by histopathological studies where the initial depth of the lesions was evident. These assessments allowed to find the depth at which treatment is efficient. Patients were treated between 2012 - 2014 in the “Carlos Andrade Marín” Hospital and “Gonzalo Gonzalez” Dermatological Hospital in Quito- Ecuador. Results: After 2 therapy sessions for suface CBC (depht middle dermis) 90% of the patients have a complete response, for nodular CBC after 4 sessions 86% of the patients have a complete response, for the CBC recurrences (neural invasion) don’t show an effective response, and for surface CEC after 6 sessions 100% of the patients have a complete response. http://dx.doi.org/10.1016/j.pdpdt.2015.07.186
PDT Brazil - Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months L.I.S. Mota, M.F.M. Brito, J.S. Belo Universidade Federal de Pernambuco - Brazil Therapy in Superficial Basal Cell Carcinoma: follow-up for 12 months. Fundamentals: Basal-cell cancer is the most prevalent non-melanoma skin cancer in Brazil and worldwide. Photodynamic therapy (PDT) is a noninvasive technique with excellent cosmetic outcome and curative results. Maintaining cure rates remains an object of study due to the recent introduction of this therapy in dermatology. Objective: Evaluate the clinical response of photodynamic therapy in superficial basal-cell carcinoma after 12 months of treatment in patients with initial complete response at the end of the third month after treatment. Methods: After curettage and application of methyl aminolevulinate, the lesion was occluded for 3 hours. Then it was discovered and submitted a 635nm LED (37 J/cm2 ), positioned eight centimeters from the patient, for eight minutes. Two sessions were realized with intervals of 14 days. Pictures were performed before treatment, at 3 and 12 months after treatment. Results: The analyses involved 35 patients, that were submitted a MAL-PDT and presented complete response in the evaluation of three months. These cancers were checked with 12 months. A maintenance of complete clinical response was observed in 85% (30/35). Conclusion: PDT-MAL is a safe and
PDT Brazil - A New Approach for Basal Cell Carcinoma Treatment Kate C. Blanco, Natalia M. Inada, Ana Paula da Silva, Pedro Russignoli, Dora P. Ramirez, Hilde H. Buzzá, Mirian D. Stringasci, Lilian T. Moriyama, Clovis Grecco, Cristina Kurachi, Vanderlei S. Bagnato São Carlos Institute of Physics, University of Sao Paulo, Brazil Non-melanoma skin cancer (NMSC) is the most prevalent cancer type in Brazil and worldwide. According to the National Institute of Cancer (INCA) at the last year, it was estimated 182,130 new cases of NMSC in Brazil. Photodynamic Therapy (PDT) has proven to be effective with an excellent cosmetic outcome and reliable treatment option. A Brazilian program was established to determine the efficacy of topical MAL-PDT using a Brazilian device (LINCE, MMOptics, Brazil) and medication (methyl aminolevulinate, PDTPharma, Brazil). During four years with financial support by BNDES (Brazilian Development Bank), we are reporting the treatment of 994 basal cell carcinoma (BCC), around all country and Latin America. Through these data it was analyzed the efficiency of the treatment 30 days after the second PDT session. Were compared the gender, age, skin type, location and size of the lesions. The conclusion of this extensive and important project has shown the efficacy PDT with 81.7% of clearance of superficial BCC and 75.1% for nodular BCC, and a small relapse rate of 1.22%. http://dx.doi.org/10.1016/j.pdpdt.2015.07.188 Prospective, double-blind, randomized placebo-controlled trial of the efficacy of lidocaine and tetracaine cream 7%/7% for pain control during PDT Ana Gabriela Salvio 1 , Pedro E Russignoli 2 , Natalia Mayumi Inada 2 , Elisangela Ramos de Oliveira 1 , Cristina Kurachi 2 , Vanderlei Salvador Bagnato 2 1 Skin Deppartment of Amaral Carvalho Hospital, Brazil 2 São Carlos Institute of Physics, University of Sao Paulo, Brazil
Photodynamic therapy (PDT) for basal cell carcinoma (BCC) treatment has been shown to be an excellent alternative to surgery, providing complete response rate of around 90% with good aesthetical outcome. However, a large proportion of patients complain local pain during irradiation, with an intensity that varies from mild to severe, and in some cases required momentary management, such as interruption of the session, nerve blocks or tumescent anaesthesia. In order to find an effective and minimally invasive strategy for the pain control during PDT, it was proposed a randomized, double-blind placebo-controlled study. Forty nodular BCC lesions less than 2 mm infiltration was selected and divided in four groups: (1) application of a FDA-approved topical anesthetic cream (Pliaglis®, Galderma, lidocaine and tetracaine cream 7%/7%) 30 minutes before illumination; (2) placebo cream application 30 minutes before illumination; (3) application of anesthetic cream immediately before illumination; (4) application of placebo cream